D
Damsan JSC
VN:ADS
Damsan JSC
VN:ADS
Price:
8 850
VND
Market Closed
Market Cap:
676.1B
VND
Add
Note
Why Create Notes?
Capture your thoughts
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Peter Lynch
Track and Analyze Performance
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Continuous Learning and Adaptation
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
Boost Decision Confidence
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Delete Note
Do you really want to delete this note?
This action cannot be undone.
ADS Alert
Damsan JSC
8850
0 (0%)
| 52 Week Range |
8 500
13 922.6891
|
| Price Target |
|
We'll email you a reminder when the closing price reaches VND.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
Delete Alert
This alert will be permanently deleted.
Ask me anything about
Damsan JSC
Balance Sheet
Balance Sheet Decomposition
Damsan JSC
Damsan JSC
| Current Assets | 1.9T |
| Cash & Short-Term Investments | 323.1B |
| Receivables | 711.2B |
| Other Current Assets | 869.5B |
| Non-Current Assets | 592.7B |
| Long-Term Investments | 367.2B |
| PP&E | 183.2B |
| Intangibles | 673.6m |
| Other Non-Current Assets | 41.5B |
| Current Liabilities | 1.5T |
| Accounts Payable | 41.7B |
| Accrued Liabilities | 7.9B |
| Short-Term Debt | 770.1B |
| Other Current Liabilities | 645B |
| Non-Current Liabilities | 84.7B |
| Long-Term Debt | 21.4B |
| Other Non-Current Liabilities | 63.3B |
Balance Sheet
Damsan JSC
Damsan JSC
Currency: VND
| Dec-2014 | Dec-2015 | Dec-2016 | Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||
| Cash & Cash Equivalents |
7 658
|
84 069
|
48 693
|
172 248
|
31 397
|
29 460
|
36 513
|
126 891
|
54 665
|
119 396
|
|
| Cash |
0
|
66 996
|
13 417
|
162 959
|
29 097
|
29 152
|
36 428
|
126 806
|
54 580
|
119 311
|
|
| Cash Equivalents |
7 658
|
17 073
|
35 276
|
9 289
|
2 300
|
308
|
85
|
85
|
85
|
85
|
|
| Short-Term Investments |
423 444
|
360 870
|
291 584
|
264 300
|
319 953
|
311 553
|
334 081
|
271 926
|
326 199
|
380 450
|
|
| Total Receivables |
131 041
|
178 158
|
221 216
|
324 432
|
413 339
|
467 383
|
426 642
|
458 692
|
568 092
|
577 966
|
|
| Accounts Receivables |
79 229
|
109 961
|
97 942
|
156 253
|
205 926
|
260 597
|
213 888
|
179 647
|
156 222
|
187 256
|
|
| Other Receivables |
51 812
|
68 197
|
123 274
|
168 179
|
207 413
|
206 786
|
212 754
|
279 045
|
411 870
|
390 711
|
|
| Inventory |
170 960
|
171 182
|
204 474
|
293 907
|
400 103
|
387 962
|
474 924
|
568 429
|
448 378
|
518 207
|
|
| Other Current Assets |
78 439
|
38 904
|
22 682
|
42 492
|
113 564
|
164 554
|
246 929
|
179 997
|
272 861
|
316 718
|
|
| Total Current Assets |
811 541
|
833 183
|
788 649
|
1 097 379
|
1 278 356
|
1 360 911
|
1 519 089
|
1 605 936
|
1 670 195
|
1 945 387
|
|
| PP&E Net |
197 546
|
174 142
|
461 403
|
451 813
|
389 903
|
329 952
|
273 735
|
225 780
|
181 696
|
205 296
|
|
| PP&E Gross |
197 546
|
174 142
|
461 403
|
451 813
|
389 903
|
329 952
|
273 735
|
225 780
|
181 696
|
205 296
|
|
| Accumulated Depreciation |
160 217
|
192 697
|
225 861
|
285 306
|
337 788
|
375 539
|
311 870
|
335 255
|
260 530
|
288 524
|
|
| Intangible Assets |
1 742
|
1 595
|
1 447
|
1 299
|
1 203
|
1 107
|
1 011
|
914
|
818
|
722
|
|
| Note Receivable |
0
|
3 576
|
3 730
|
3 607
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Long-Term Investments |
34 206
|
30 667
|
0
|
0
|
31 575
|
32 037
|
32 795
|
140 095
|
303 349
|
316 384
|
|
| Other Long-Term Assets |
16 141
|
12 522
|
9 980
|
11 033
|
11 871
|
9 477
|
11 262
|
12 444
|
25 637
|
36 004
|
|
| Total Assets |
1 061 176
N/A
|
1 055 685
-1%
|
1 265 210
+20%
|
1 565 132
+24%
|
1 712 908
+9%
|
1 733 483
+1%
|
1 837 891
+6%
|
1 985 169
+8%
|
2 181 695
+10%
|
2 503 792
+15%
|
|
| Liabilities | |||||||||||
| Accounts Payable |
47 512
|
145 286
|
206 998
|
123 043
|
150 568
|
91 643
|
110 751
|
95 275
|
99 701
|
56 877
|
|
| Accrued Liabilities |
7 043
|
4 400
|
7 683
|
8 175
|
9 495
|
10 124
|
7 811
|
13 446
|
11 079
|
11 264
|
|
| Short-Term Debt |
0
|
0
|
0
|
541 544
|
642 879
|
663 516
|
639 519
|
580 682
|
664 610
|
793 106
|
|
| Current Portion of Long-Term Debt |
593 640
|
595 404
|
608 441
|
37 061
|
16 826
|
13 586
|
27 858
|
46 370
|
46 776
|
28 980
|
|
| Other Current Liabilities |
26 324
|
13 809
|
35 707
|
223 227
|
298 911
|
438 269
|
531 914
|
563 689
|
542 562
|
582 704
|
|
| Total Current Liabilities |
674 518
|
758 899
|
858 829
|
933 050
|
1 118 680
|
1 217 138
|
1 317 853
|
1 299 462
|
1 364 727
|
1 472 932
|
|
| Long-Term Debt |
156 260
|
55 260
|
149 987
|
201 253
|
142 252
|
113 237
|
97 895
|
99 895
|
157 957
|
100 368
|
|
| Deferred Income Tax |
0
|
0
|
14
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Minority Interest |
0
|
11 671
|
15 029
|
19 970
|
42 886
|
38 217
|
36 363
|
41 140
|
41 507
|
179 886
|
|
| Other Liabilities |
62 526
|
7 421
|
0
|
0
|
0
|
0
|
0
|
1 910
|
1 915
|
12 241
|
|
| Total Liabilities |
893 303
N/A
|
833 250
-7%
|
1 023 859
+23%
|
1 154 273
+13%
|
1 303 817
+13%
|
1 368 593
+5%
|
1 452 111
+6%
|
1 442 406
-1%
|
1 566 107
+9%
|
1 765 427
+13%
|
|
| Equity | |||||||||||
| Common Stock |
100 700
|
160 700
|
168 735
|
255 178
|
255 178
|
255 178
|
280 695
|
380 695
|
437 790
|
583 947
|
|
| Retained Earnings |
60 852
|
55 414
|
64 992
|
86 330
|
82 676
|
36 960
|
32 098
|
89 239
|
99 544
|
77 998
|
|
| Additional Paid In Capital |
323
|
323
|
323
|
60 284
|
60 284
|
60 284
|
60 284
|
60 125
|
60 125
|
62 638
|
|
| Other Equity |
5 998
|
5 998
|
7 301
|
9 067
|
10 953
|
12 469
|
12 704
|
12 704
|
18 128
|
13 781
|
|
| Total Equity |
167 872
N/A
|
222 434
+33%
|
241 351
+9%
|
410 859
+70%
|
409 091
0%
|
364 891
-11%
|
385 780
+6%
|
542 763
+41%
|
615 588
+13%
|
738 365
+20%
|
|
| Total Liabilities & Equity |
1 061 176
N/A
|
1 055 685
-1%
|
1 265 210
+20%
|
1 565 132
+24%
|
1 712 908
+9%
|
1 733 483
+1%
|
1 837 891
+6%
|
1 985 169
+8%
|
2 181 695
+10%
|
2 503 792
+15%
|
|
| Shares Outstanding | |||||||||||
| Common Shares Outstanding |
17
|
27
|
27
|
40
|
40
|
40
|
40
|
44
|
50
|
58
|
|
Switch to:
Switch to:
See Also
Discover More
You don't have any saved screeners yet
